Based on the BB Biotech AG stock forecast from 0 analysts, the average analyst target price for BB Biotech AG is not available over the next 12 months. BB Biotech AG’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BB Biotech AG is Bullish , which is based on 7 positive signals and 2 negative signals. At the last closing, BB Biotech AG’s stock price was EUR 41.60. BB Biotech AG’s stock price has changed by -2.35% over the past week, -9.96% over the past month and -14.40% over the last year.
No recent analyst target price found for BB Biotech AG
No recent average analyst rating found for BB Biotech AG
Company Overview BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland. Address: Seestrasse 16, Küsnacht, Switzerland, CH-8700 Read Less
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fun...Read More
Frequently Asked Questions About BB Biotech AG (BBZA:XETRA) Stock
Stock Target Advisor's fundamental analysis for BB Biotech AG's stock is Bullish .
BBZA:XETRA stock's dividend yield is 4.75%.
Our analysis grades BBZA:XETRA stock's dividend yield at A+. This means that BBZA:XETRA stock's dividend yield is above 100% of the stocks in the Biotechnology sector in the XETRA exchange.
Based on this BBZA:XETRA may be a good dividend stock for its sector.
Unfortunately we do not have enough data on BBZA:XETRA's stock to indicate what its average analyst target is.
BBZA:XETRA stock's Price/Earning ratio is 4.51.
Our analysis grades BBZA:XETRA stock's Price / Earning ratio at A+. This means that BBZA:XETRA stock's Price/Earning ratio is above 0% of the stocks in the Biotechnology sector in the XETRA exchange.
Based on this BBZA:XETRA may be undervalued for its sector.
The last closing price of BBZA:XETRA's stock was EUR 41.60.
The most recent market capitalization for BBZA:XETRA is EUR 2.27B.
Unfortunately we do not have enough analyst data on BBZA:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains BB Biotech AG's stock.
As per our most recent records BB Biotech AG has 10 Employees.
BB Biotech AG's registered address is Seestrasse 16, Kusnacht, Switzerland, 8700.
You can get more information about it from BB Biotech AG's website at https://www.bbbiotech.ch/en/bb-biotech/.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BBZA:XETRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
